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Ashley Woodcock, MD,1 Angela Simpson, MD,1 and Adnan Custovic, PhD1
Background: We investigated the effects of sensitization and ex-
posure to common domestic allergens on longitudinal changes in
lung function and bronchial hyperresponsiveness.
Methods: Subjects attended 2 visits that were 4 years apart. Skin
prick testing was performed and household dust samples were
collected for quantification of mite, dog, and cat allergens at base-
line. Measurements of lung function, exhaled nitric oxide, and
bronchial hyperresponsiveness were completed at both visits.
Results: Dust samples were collected in 165 of the 200 subjects
completing both visits. Mean length of follow-up was 47 months.
Bronchial hyperresponsiveness, measured at both visits in 86 sub-
jects, deteriorated in those exposed to high mite allergen levels
compared with those not exposed mean (95% CI) doubling dose
change PD20  0.44 (1.07 to 0.19) vs 0.82 (0.27 to 1.36), but
improved in those exposed to high dog allergen levels compared
with those not exposed 1.10 (0.33 to 1.86) vs 0.10 (0.39 to 0.58).
The associations were significant in the multivariate models. Cat
allergen exposure was not associated with any changes in lung
function, exhaled nitric oxide, or bronchial hyperresponsiveness.
Conclusions: In a 4-year prospective cohort of persons with asthma,
exposure to high levels of dust mite allergens at baseline was associated
with a subsequent increase in bronchial hyperresponsiveness.
Key Words: asthma, allergens, environmental exposure,
longitudinal studies
(WAO Journal 2009; 2:83–90)
INTRODUCTION
Progressive deterioration in symptoms and an accelerateddecline in lung function are features of the natural history
of disease in a proportion of patients with asthma.1 Identify-
ing factors associated with this decline would be an important
step in the development of strategies aimed at preventing
long-term deterioration, compared with current recommenda-
tions that principally address short-term symptom control.2
Among various factors associated with the decline over
time, the clearest evidence to date has linked cigarette smok-
ing to a loss of lung function.3,4 Although patients with
bronchial hyperresponsiveness (BHR) are less likely to de-
velop irreversible airflow obstruction, the presence of BHR
has been associated with an accelerated decline in lung
function.5,6 There is no clear link between atopic sensitization
and decline in lung function in asthma. However, the absolute
level of specific IgE has been related to the development of
wheezing in children and a number of positive skin tests to
increasing BHR in adults.7,8
The ASMAL (ASsessment of Manchester Asthmatics
Longitudinally) cohort was set up to investigate factors asso-
ciated with asthma control and lung function.9–11 Baseline
cross-sectional data suggested that, for sensitized individuals,
domestic exposure to high levels of sensitizing allergens is
associated with poorer lung function.11 Surprisingly, even
among nonsensitized persons with asthma, high levels of
exposure to dust mite or dog allergen were associated with
increased BHR.10 On the basis of these findings, we hypoth-
esized that allergen sensitization and high allergen exposure
would be associated with a decline in lung function and
increased BHR and airway inflammation over time. Thus,
within the ASMAL cohort, we aimed to investigate the
effects of sensitization and domestic exposure to common
inhalant allergens (dust mite, cat, and dog) on longitudinal
changes in lung function and BHR over a 4-year period.
METHODS
Participants
We recruited subjects with physician-diagnosed asthma
(asthma symptoms in the previous 12 months, treatment with a
minimum of a short-acting bronchodilator, and no exacerbations
for 4 weeks before recruitment) as previously described.10,11 The
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study was approved by the local research ethics committee;
subjects provided written informed consent.
Participants attended 2 visits 4 years apart. Previsit
medication was withheld as follows: short-acting bronchodi-
lators, 6 hours; long-acting bronchodilators, theophyllines,
and leukotriene receptor antagonists, 12 hours; antihista-
mines, 48 hours.
Procedures
Exhaled Nitric Oxide
Exhaled nitric oxide (eNO) was measured using a
chemiluminescence analyzer (LR2000; Logan Research,
Rochester, UK) according to published guidelines.12 Subjects
exhaled from inspiratory capacity to residual volume at a
controlled rate (6 L/min) into a wide-bore minimal-resistance
Teflon tube. Response time (10%–90%) was0.6 seconds
and the sampling rate was 250 L/min; the final value was
recorded as the mean of 2 maneuvers.
Spirometry
Spirometry was performed according to ATS guide-
lines13 (Microlab 3000; MicroMedical, Rochester, UK).
Bronchial Challenge
Bronchial challenge was performed at baseline using
either methacholine or histamine. Supply problems precluded
the use of the same challenge in all subjects, but previous
studies have demonstrated dose equivalence;14,15 analysis of
our data found no evidence of differences between the chal-
lenges and no bias in terms of outcomes.10,11 At the follow-up
visit, all subjects had histamine challenge. For either chal-
lenge, a modified Yan technique was used16 Koko DigiDoser
dosimeter (PDS Research, Louisville, Colo) and “646” neb-
ulizer pots (DeVilbiss, Somerset, Pa). Baseline FEV1
(FEV1, forced expiratory volume in 1 second) measure-
ment (best of 3) was performed 1 minute after inhalation of
isotonic saline, then cumulative doubling doses of the
challenge solution were administered, and FEV1 was mea-
sured 1 minute after each dose. When the FEV1 had fallen
by 20% or more, the challenge was terminated and PD20
calculated by linear interpolation. Where the FEV1 did not
fall by 20% despite the maximum dose of challenge solution,
a PD20 of 12 mg was assigned (1 doubling dose above the
maximum given).
TABLE 1. Characteristics of Subgroups Included in the Analysis*
Attended Both Visits Allergen Samples Collected Bronchial Challenge at Both Visits
Yes No Yes No Yes No
N  200 N  199 N  165 N  35 N  86 N  79
Age (years) 44 35† 45 41 41 50†
(n  195)
Sex (% males) 40% 44% 39% 43% 31% 48%†
Years with asthma 23 17† 23 23 20 25†
(n  179) (n  132) (n  150) (n  31) (n  72) (n  78)
% on ICS treatment 72% 58%† 73% 66% 60% 86%†
(n  199) (n  34)
ICS dose (g) 967 1034 948 1064 830 1042
(n  137) (n  101) (n  115) (n  22) (n  51) (n  64)
Smoking status (%)
Never 61% 61% 59% 71% 65% 52%
Ex 28% 23% 30% 17% 27% 33%
Current 12% 16% 12% 11% 8% 15%
Spirometry
FEV1 (l) 2.50 3.05† 2.51 2.49 2.87 2.11†
(n  197) (n  199) (n  164) (n  33) (n  78)
FVC (l) 3.48 3.80† 3.48 3.46 3.73 3.27†
(n  166) (n  110) (n  137) (n  29) (n  63) (n  74)
Reversibility (%) 14% 13% 14% 14% 8% 18%†
(n  124) (n  73) (n  106) (n  18) (n  40) (n  66)
PD20 GM (g) 0.412 0.538 0.422 0.398 0.394 0.590
(n  118) (n  146) (n  103) (n  15) (n  17)
eNO GM (ppb) 11.09 9.76 11.04 11.41 10.77 11.35
(n  173) (n  160) (n  149) (n  24) (n  80) (n  69)
Atopy (%) 84% 83% 82% 94% 85% 80%
(n  195) (n  195) (n  164) (n  31) (n  85) (n  79)
*Where data not available for all subjects in group, the number included in the analysis is shown in parentheses.
†P  0.05 “no” vs “yes”.
ICS, inhaled corticosteroids.
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Sensitization
Sensitization was ascertained by skin prick testing
(mite, cat, and dog; Bayer, Elkhart, Ind), and sensitization is
defined as a mean wheal diameter of at least 3 mm greater
than the negative control.
Allergen Exposure
Allergen exposure was assessed in dust samples col-
lected from homes by vacuuming a 1-m2 area of living room
carpet and mattress for 2 minutes. Mite, cat, and dog allergen
levels were measured using monoclonal antibody-based en-
zyme-linked immunosorbent assays.17–19
Statistical Analysis
Statistical analysis was performed using SPSS 12.0 for
Windows. The primary end point was change in lung function
(FEV1 and BHR) over time in relation to sensitization status and
allergen exposure; 250-mL change in FEV1 and 1 doubling dose
change in PD20 were considered relevant. On the basis of the
data at the baseline visit, a sample size of 200 provided 80%
power to detect a 250-mL change in FEV1 and a sample size of
106 to detect a 1 doubling dose change in PD20 ( error 0.05).
Allergen levels, eNO, and PD20 were normalized using log-
transformation. Between-group differences for nominal vari-
ables were investigated using the 2 test. Lung function vari-
ables at 2 visits were compared using the paired t test, both
overall and for subgroups. Change in lung function over time
was calculated and between-group comparisons were made
initially by independent t tests. Further comparisons were per-
formed using analysis of variance (ANOVA), with possible
confounders included in the multivariate model (P 0.5).
ANOVA was employed to investigate possible interaction be-
tween exposure and sensitization.
RESULTS
Participants
Two hundred of the original cohort of 399 persons with
asthma attended the follow-up visit, at mean 47 months
(range of 25–68 months) after the baseline assessment. Sub-
jects attending for follow-up tended to be older (44 vs 35
years old, P 0.001) with a longer duration of asthma (23 vs
17 years, P  0.001), were more likely treated with inhaled
corticosteroids (72% vs 58%, P 0.005), and had worse lung
function (FEV1  2.50 L vs 3.05 L, P 0.001) compared
with those who did not attend (Table 1).
Of 200 subjects with a longitudinal data collection, 165
had domestic allergen levels determined at visit 1; there were no
differences in any of the measurements between subjects with or
without allergen exposure assessment. Of these 165, 103 had a
bronchial challenge at visit 1 (reasons for not being tested: 31/62
had FEV1 60%; the remaining subjects declined the test) and
110 at visit 2 (22/55 had FEV1 60%; the rest declined the
test). The 86 subjects who had bronchial challenge at both visits
were less often treated with inhaled corticosteroids (60% vs
86%, P 0.001), had better lung function (FEV1  2.87 L vs
2.11 L, P 0.001; FVC  3.73 L vs 3.27 L, P 0.001; FVC,
forced vital capacity), and were less likely to be male (31% vs
48%, P  0.04). Characteristics of the study population are
presented in Table 2.
Change in Lung Function, eNO, and BHR
Over Time
The change in lung function, eNO, and BHR between 2
visits in the whole population and among sensitized and
nonsensitized subjects are presented in Table 3. In all sub-
jects, FEV1 (% predicted value) increased over time from
82.0 to 84.2% predicted 95% CI for difference 0.2–4.1%
predicted, P  0.03, although the absolute FEV1 did not
change. There was a 1.4-fold decrease in geometric mean
(GM) eNO (95% CI for difference 1.2–1.6-fold, P  0.001),
and no significant change in BHR.
TABLE 2. Baseline Characteristics of Participants With
Allergen Samples Collected
n
Age (years) 165 Mean 45
Range 10 to 67
Sex 165 39% male
Years with asthma 150 Mean 23
Range 1 to 59
Age diagnosed with asthma
(years)
150 Mean 23
Range 0 to 58
ICS treatment 165 73%
ICS dose (BDP dose
equivalent, g)
115 Mean 948
Median 800
Range 100 to 4000
Smokers 165 Never 59%
Ex 30%
Current 12%
Lung function
FEV1 (l) 164 Mean 2.51
Range 0.71 to 4.91
FVC (l) 137 Mean 3.48
Range 1.41 to 7.13
PD20 (mg) 103 GM 0.422
95% CI 0.303 to
0.585
Classification of BHR 103 None or borderline 10%
(PD20  4 mg)
Mild 20%
(PD20  1–4 mg)
Moderate to severe 70%
(PD20  1 mg)
Exhaled nitric oxide (ppb) 149 GM 11.04
95% CI 9.66 to
12.61
Atopic (SPT done in 164
subjects)
82%
Sensitized to:
Dust mite 61%
Cat 49%
Dog 43%
BDP, beclomethasone dipropionate; SPT, skin prick testing.
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Allergen Sensitization and Change in Lung
Function, eNO, and BHR
Among atopic subjects, mean FEV1 improved from
82.1 to 84.8% predicted (95% CI for difference 0.5–4.9%
predicted, P 0.015) and FVC from 96.2 to 99.5% predicted
(95% CI for difference 0.2–6.4% predicted, P  0.038),
although the absolute FEV1 and FVC did not change (Table
2). ENO decreased 1.5-fold (95% CI for difference 1.2–1.7-
fold, P  0.001). No such changes were observed in the
nonatopic group.
Role of Allergen Exposure
Subjects were classified as being exposed to high levels
of domestic allergens based on previously proposed criteria
(2 g/g Der p 1, 10 g/g Fel d 1, and 10 g/g Can f 1
in either carpet or mattress). Exposure to cat allergen was not
associated with any changes in lung function, eNO, or BHR
(Table 4).
We found no difference in the change in lung function
or eNO between subjects exposed or not exposed to the high
level of dust mite allergen or dog allergen, although those not
exposed to dog allergen did show an increase in FEV1 over
baseline of 2.4% predicted that was not seen in the dog-
exposed group (Tables 5 and 6). BHR improved among
subjects who were not exposed to high Der p 1 levels from
GM PD20  359 g to GM PD20  632 g; no such
improvement was observed in the exposed group (GM
PD20  444 g at baseline vs GM PD20  327 g at
follow-up), and there was a 1.26 doubling dose (DD) differ-
ence in the change versus baseline comparing the nonexposed
group to the exposed group (95% CI for difference 0.44–2.08
DD, P  0.003). In the multivariate ANOVA model adjust-
ing for the potential confounders (age, inhaled steroid use and
dose, smoking status, baseline PD20, sensitization to house
dust mite, and exposure to high levels of dog allergen), high
exposure to dust mite allergen remained significantly and
independently associated with the change in BHR estimated
marginal means (95% CI): exposed 0.42 (0.94 to 0.10)
DD; nonexposed 0.86 (0.40–1.31) DD; P  0.001 for dif-
ference; Table 5.
In subjects exposed to high Can f 1 level, BHR im-
proved from GM PD20 394 g to GM PD20 843 g over
a period of 4 years, or a mean 1.10 DD improvement (95% CI
for difference 0.39–1.80 DD, P  0.005). This improvement
was not seen in the nonexposed group (baseline GM PD20 
394 g vs GM PD20  422 g at 4 years). There was a 1.01
DD difference in change versus baseline comparing the
exposed group to the nonexposed group (95% CI for differ-
ence –0.01 to 2.12 DD, P  0.07). In the multivariate
ANOVA model adjusting for the potential confounders (age,
TABLE 3. Change in Spirometry, eNO, and BHR Between 2 Visits in the Whole Population and for Atopic and Nonatopic
Subjects Only*
FEV1 FEV1 FVC FVC eNO PD20
(L) (% Predicted) (L) (% Predicted) (ppb) (Doubling Doses)
All subjects N 163 162 137 137 118 85
Mean 0.00 2.27† 0.02 2.33 3.25† 0.29
(95% CI) (0.06 to 0.06) (0.29–4.26) (0.07 to 0.12) (0.50 to 5.17) (1.22–1.62) (0.13 to 0.72)
Atopic N 134 133 110 110 97 72
Mean 0.00 2.72† 0.04 3.30† 3.93† 0.39
(95% CI) (0.06 to 0.05) (0.54–4.90) (0.06 to 0.14) (0.18–6.42) (1.25–1.73) (0.04 to 0.83)
Nonatopic N 29 29 27 27 21 13
Mean 0.00 0.21 0.06 1.61 1.10 0.27
(95% CI) (0.18 to 0.17) (4.83 to 5.24) (0.32 to 0.21) (8.57 to 5.35) (0.86–1.61) (1.84 to 1.30)
*Lung function and BHR: mean changes (95% CI). eNO: geometric mean (95% CI for ratio).
†P  0.05 vs baseline.
TABLE 4. Change in Lung Function, eNO, and BHR Between 2 Visits According to Living Room Cat Allergen Exposure*
Fel d 1 FEV1 FEV1 FVC FVC eNO PD20 Between Group
(Living Room) (L) (% Predicted) (L) (% Predicted) (ppb) (Doubling Doses) Doubling Dose
Difference PD20
(95% CI)
Not exposed N 115 114 95 95 81 60 0.24
Mean 0.00 1.93 0.03 2.18 3.09† 0.33 (0.70 to 1.17)
(95% CI) (0.07 to 0.06) (0.48 to 4.35) (0.08 to 0.14) (1.26 to 5.62) (1.14–1.68) (0.15 to 0.81)
Exposed N 49 49 42 42 38 26 t test, P  0.615
Mean 0.03 2.68 0.01 2.67 3.58† 0.10 ANOVA, P  0.984
(95% CI) (0.15 to 0.09) (0.92 to 6.28) (0.17 to 0.19) (2.55 to 7.90) (1.20–1.75) (0.82 to 1.02)
*Lung function and BHR: mean changes (95% CI). eNO: geometric mean (95% CI for ratio).
†P  0.05 vs baseline.
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inhaled steroid use and dose, smoking status, exposure to
house dust mite allergen, and baseline PD20), high exposure
to dog allergen was significantly and independently associ-
ated with the improvement in BHR estimated marginal
means (95% CI): exposed 1.17 (0.35–1.99) DD; nonexposed
0.08 (0.28 to 0.45) DD; P 0. 019 for difference; Table 6.
To minimize the possibility that a change in dog own-
ership status may have confounded the results, the ANOVA
model was repeated, first including “lost a dog between visits
1 and 2” as a confounder and second excluding from the
analysis those subjects who had lost their dog. There was no
change in the results in either case. For example, when
subjects who got rid of their dog between visits 1 and 2 were
excluded, there was again no change in BHR for those not
exposed to high levels of dog allergen n  70, mean (95%
CI) 0.11 (0.39 to 0.60) DD change but BHR decreased in
those exposed to high Can f 1 levels n  11, mean (95% CI)
1.10 (0.20–1.99) DD change, P  0.022. High dog allergen
exposure was again significantly associated with the change
in BHR in the multivariate ANOVA model (confounders:
age, number of years with asthma, inhaled steroid use and
dose, smoking status, dog sensitization, exposure to house
dust mite allergen, and baseline PD20; P  0.04).
For each allergen there was no significant effect of the
interaction between exposure and sensitization in the multi-
variate models (data not shown). This was indirectly con-
firmed when we carried out the analysis according to the
exposure and sensitization status (not sensitized/not exposed,
not sensitized/exposed, sensitized/not exposed, and sensi-
tized/exposed; Fig. 1).
We then compared the actual allergen levels between
individuals with 1 DD increase in PD20 (deterioration), 1
DD decrease in PD20 (improvement), and no change in BHR
(the difference within 1 DD between 2 visits). Der p 1
decreased significantly, whereas Can f 1 increased signifi-
cantly with the improving BHR (Fig. 2). Subjects with 1
DD deterioration in PD20 or more had 2.9-fold higher levels
of Der p 1 detected in their mattress compared with those
with no change or an improvement in PD20 (95% CI for
difference 0.87–9.31 g/g; multivariate ANOVA model, P
0.046). For dog allergen, subjects with 1 DD improvement
in PD20 were exposed to 2.7-fold more dog allergen com-
pared with those with no improvement or a deterioration in
PD20 (95% CI for difference 0.07–2.81 g/g; multivariate
ANOVA model, P  0.04).
DISCUSSION
Principal Findings
We have shown that exposure to high levels of dust
mite allergen in persons with asthma was associated with a
deterioration in BHR over a period of 4 years. The converse
was true for dog allergen in that high exposure was associated
with an improvement in BHR. These findings were in a large
TABLE 6. Change in Lung Function, eNO, and BHR Between 2 Visits According to Living Room Exposure to Dog Allergen*
Can f 1 FEV1 FEV1 FVC FVC eNO PD20 Between Group
(Living Room) (L) (% Predicted) (L) (% Predicted) (ppb) (Doubling Doses) Doubling Dose
Difference PD20
(95% CI)
Not exposed N 125 124 103 103 84 72 1.00
Mean 0.01 2.43† 0.04 2.51 3.39† 0.10 (2.14 to 0.14)
(95% CI) (0.06 to 0.07) (0.36–4.50) (0.07 to 0.14) (0.50 to 5.51) (1.20–1.68) (0.39 to 0.58)
Exposed N 39 39 34 34 35 14 t test, P  0.085
Mean 0.06 1.31 0.01 1.81 2.92† 1.10† ANOVA, P  0.019
(95% CI) (0.19 to 0.07) (3.93 to 6.55) (0.24 to 0.22) (5.44 to 9.06) (1.03–1.85) (0.33–1.86)
*Lung function and BHR: mean changes (95% CI). eNO: geometric mean (95% CI for ratio).
†P  0.05 vs baseline.
TABLE 5. Change in Lung Function, eNO, and BHR Between 2 Visits According to Mattress Exposure to Dust Mite Allergen*
Der p 1 FEV1 FEV1 FVC FVC eNO PD20 Between Group
(Mattress) (L) (% Predicted) (L) (% Predicted) (ppb) (Doubling Doses) Doubling Dose
Difference PD20
(95% CI)
Not exposed N 84 84 67 67 58 48 1.26
Mean 0.03 1.77 0.01 1.73 2.89† 0.82†‡ (0.44 to 2.08)
(95% CI) (0.12 to 0.05) (1.14 to 4.69) (0.13 to 0.15) (2.49 to 5.95) (1.16–1.59) (0.27–1.36)
Exposed N 80 79 70 70 61 38 t test, P  0.003
Mean 0.01 2.57 0.04 2.91 3.60† 0.44 ANOVA, P  0.001
(95% CI) (0.06 to 0.08) (0.17 to 5.31) (0.09 to 0.17) (1.00 to 6.82) (1.14–1.85) (1.07 to 0.19)
*Lung function and BHR: mean changes (95% CI). eNO: geometric mean (95% CI for ratio).
†P  0.05 vs baseline; ‡P  0.05 vs exposed.
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group of well-characterized persons with asthma and re-
mained significant after potential confounders were intro-
duced to the model. There was no independent effect of
sensitization to the relevant allergen in this model.
Limitations
We are aware of the possible selection bias in our data
set. Only a proportion of the original attendees were reviewed
after 4 years, and those who agreed to attend for a second visit
may not be representative of the whole cohort. Although we
obtained domestic dust samples from more than 80% of these
subjects, one of the primary end points (change in BHR) was
measured at both visits in only 86 subjects. As we have
acknowledged, these were not entirely typical of the group as
a whole, in general, having milder disease requiring less
treatment and with better lung function. This is in part
because (for the reasons of safety) we did not carry out
bronchial challenge in patients with marked airway obstruc-
tion (FEV1  60% predicted), and thus more severe asthma.
Another important potential confounder in our study is
the high proportion of subjects who were taking inhaled
steroids, at a reasonably high mean dose. This may well
account for the mean improvements seen overall in eNO and
FEV1 percentage predicted over the study period. We in-
cluded inhaled steroid use and dose as a covariate in the
multivariate models where appropriate for this reason. We
used a skin prick test wheal of minimum 3 mm greater than
control to determine atopy. It is possible therefore that we
underestimated sensitization, and future studies should
include measurements of specific radioallergosorbent test IgE
to minimize this possibility.
Regarding the unexpected findings with dog allergen
exposure, there is a chance of type II error with only 14
subjects exposed. This may of course represent self-selection,
with persons having more severe asthma avoiding dog expo-
sure in the home, although there were no differences in other
FIGURE 2. Mean (2 SE) log allergen levels for mattress
mite (top) and living room dog (bottom) categorized by
doubling dose change in PD20.
FIGURE 1. Mean (2 SE) PD20 as doubling dose change
from baseline by sensitization and exposure to mite (top)
and dog (bottom). NS, not sensitized; NE, not exposed; S,
sensitized; E, exposed.
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markers of asthma severity, such as PD20, eNO, FEV1, or
inhaled corticosteroid dose at baseline between groups ac-
cording to dog exposure (data not shown). It is also possible
that domestic allergen exposure changed over the 4-year
period, although a recent study has demonstrated acceptable
stability over a similar period,20 at least for mite and cat
allergens.
Meaning of the Study
That exposure to high levels of house dust mite allergen
was associated with deteriorating BHR was not an unex-
pected finding. House dust mite allergens include a number of
proteases and trypsins that may disrupt cell membranes and
have direct pro-inflammatory actions, and they also mediate
airway inflammation through IgE activation.21 They may
therefore contribute to the persistence of airway inflammation
over time, and perhaps a consequent increase in bronchial
hyperresponsiveness.
Early-life exposure to dogs is associated with a reduced
likelihood of developing asthma in children,22 but there are
no data for adults with asthma. It is interesting therefore that
we have found an association between exposure to high levels
of dog allergen and improvement of BHR. We considered the
possibility that subjects may have gotten rid of their dog
between visits, but even after controlling for this, we discov-
ered that the association remained the same. It is also possible
that dog ownership per se conferred the observed improve-
ments. However, when we tested for an association between
dog ownership and change in BHR, we found none (data not
shown). One other possibility is that tolerance resulting from
high dog allergen exposure may have developed in the skin
prick negative subjects and could be responsible for some of
the difference seen. Although there was no correlation be-
tween levels of dust mite and dog allergens (data not shown),
it is still possible of course that there are other important
confounding variables that we have not measured, such as
domestic levels of endotoxin or fungal spores. The relation-
ship between exposure to endotoxin or mold and asthma is
unclear. Some studies have shown an inverse association with
allergic sensitization and asthma in children,23,24 but others
demonstrated increased risk for asthma prevalence.25
The majority of our subjects were atopic, and this group
as a whole improved over time in terms of lung function and
eNO, whereas the nonatopic group did not. Dijkstra and
colleagues followed 122 persons with asthma for more than
23 years and reported no association between atopy and lung
function change.26 However, atopy was more common (98%
vs 87%) in the 159 subjects excluded from the analysis, either
because they had never used inhaled corticosteroids or had
insufficient longitudinal data. It is likely, therefore, that this
group had less severe asthma. Another longitudinal study
reported a lower prevalence of irreversible airflow obstruc-
tion in persons with atopic asthma.6 It is likely that different,
although not necessarily independent, factors are important
when considering asthma development, asthma severity, and
asthma progression. It is also likely that these factors may
differ between recognized asthma phenotypes, such as late
onset versus early onset or atopic versus nonatopic.
CONCLUSIONS
We have demonstrated that exposure to high levels of
house dust mite allergen in the home, over a period of 4 years,
is associated with deteriorating bronchial hyperresponsiveness,
whereas the converse is true for dog allergen exposure. If these
findings are confirmed over longer periods of time, further
investigation into the favorable association between dog allergen
exposure and prognosis will be required, and possibly targeted
intervention in those exposed to high levels of house dust mite
allergen, irrespective of their sensitization status.
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